Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189
Background - In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-c...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
22 April 2021
|
| In: |
Annals of oncology
Year: 2021, Jahrgang: 32, Heft: 7, Pages: 881-895 |
| ISSN: | 1569-8041 |
| DOI: | 10.1016/j.annonc.2021.04.008 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.annonc.2021.04.008 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753421011467 
|
| Verfasserangaben: | D. Rodríguez-Abreu, S.F. Powell, M.J. Hochmair, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Dómine, S.Y. Cheng, H.G. Bischoff, N. Peled, M. Reck, R. Hui, E.B. Garon, M. Boyer, T. Kurata, J. Yang, M.C. Pietanza, F. Souza & M.C. Garassino |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1763723674 | ||
| 003 | DE-627 | ||
| 005 | 20240414193244.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210720s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2021.04.008 |2 doi | |
| 035 | |a (DE-627)1763723674 | ||
| 035 | |a (DE-599)KXP1763723674 | ||
| 035 | |a (OCoLC)1341419714 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Rodríguez-Abreu, Delvys |e VerfasserIn |0 (DE-588)1237278147 |0 (DE-627)1763723364 |4 aut | |
| 245 | 1 | 0 | |a Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC |b protocol-specified final analysis from KEYNOTE-189 |c D. Rodríguez-Abreu, S.F. Powell, M.J. Hochmair, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Dómine, S.Y. Cheng, H.G. Bischoff, N. Peled, M. Reck, R. Hui, E.B. Garon, M. Boyer, T. Kurata, J. Yang, M.C. Pietanza, F. Souza & M.C. Garassino |
| 264 | 1 | |c 22 April 2021 | |
| 300 | |a 15 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Available online 22 April 2021 | ||
| 500 | |a Gesehen am 20.07.2021 | ||
| 520 | |a Background - In the phase III KEYNOTE-189 study (NCT02578680), pembrolizumab plus pemetrexed and platinum-based chemotherapy (pemetrexed-platinum) significantly improved overall survival (OS) and progression-free survival (PFS) in patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) versus placebo plus pemetrexed-platinum. We report updated efficacy outcomes from the protocol-specified final analysis, including outcomes in patients who crossed over to pembrolizumab from pemetrexed-platinum and in patients who completed 35 cycles (∼2 years) of pembrolizumab. - Patients and methods - Eligible patients were randomized 2 : 1 to receive pembrolizumab 200 mg (n = 410) or placebo (n = 206) every 3 weeks (for up to 35 cycles, ∼2 years) plus four cycles of pemetrexed (500 mg/m2) and investigators’ choice of cisplatin (75 mg/m2) or carboplatin (area under the curve 5 mg·min/ml) every 3 weeks, followed by pemetrexed until progression. Patients assigned to placebo plus pemetrexed-platinum could cross over to pembrolizumab upon progression if eligibility criteria were met. The primary endpoints were OS and PFS. - Results - After a median follow-up of 31.0 months, pembrolizumab plus pemetrexed-platinum continued to improve OS [hazard ratio (HR), 0.56; 95% confidence interval (CI), 0.46-0.69] and PFS (HR, 0.49; 95% CI, 0.41-0.59) over placebo plus pemetrexed-platinum regardless of programmed death-ligand 1 expression. Objective response rate (ORR) (48.3% versus 19.9%) and time to second/subsequent tumor progression on next-line treatment (PFS2; HR, 0.50; 95% CI, 0.41-0.61) were improved in patients who received pembrolizumab plus pemetrexed-platinum. Eighty-four patients (40.8%) from the placebo plus pemetrexed-platinum group crossed over to pembrolizumab on-study. Grade 3-5 adverse events occurred in 72.1% of patients receiving pembrolizumab plus pemetrexed-platinum and 66.8% of patients receiving placebo plus pemetrexed-platinum. Fifty-six patients completed 35 cycles (∼2 years) of pembrolizumab; ORR was 85.7% and 53 (94.6%) were alive at data cut-off. - Conclusions - Pembrolizumab plus pemetrexed-platinum continued to show improved efficacy outcomes compared with placebo plus pemetrexed-platinum, with manageable toxicity. These findings support first-line pembrolizumab plus pemetrexed-platinum in patients with previously untreated metastatic nonsquamous NSCLC. | ||
| 650 | 4 | |a chemotherapy | |
| 650 | 4 | |a nonsquamous non-small-cell lung cancer | |
| 650 | 4 | |a pembrolizumab | |
| 700 | 1 | |a Bischoff, Helge |d 1958- |e VerfasserIn |0 (DE-588)111184576 |0 (DE-627)389658286 |0 (DE-576)167287249 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology |d Amsterdam [u.a.] : Elsevier, 1990 |g 32(2021), 7, Seite 881-895 |h Online-Ressource |w (DE-627)320428796 |w (DE-600)2003498-2 |w (DE-576)098134345 |x 1569-8041 |7 nnas |a Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC protocol-specified final analysis from KEYNOTE-189 |
| 773 | 1 | 8 | |g volume:32 |g year:2021 |g number:7 |g pages:881-895 |g extent:15 |a Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC protocol-specified final analysis from KEYNOTE-189 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.annonc.2021.04.008 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S0923753421011467 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20210720 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 111184576 |a Bischoff, Helge |m 111184576:Bischoff, Helge |d 910000 |d 950000 |d 950900 |e 910000PB111184576 |e 950000PB111184576 |e 950900PB111184576 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 11 | ||
| 999 | |a KXP-PPN1763723674 |e 3956068750 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["D. Rodríguez-Abreu, S.F. Powell, M.J. Hochmair, S. Gadgeel, E. Esteban, E. Felip, G. Speranza, F. De Angelis, M. Dómine, S.Y. Cheng, H.G. Bischoff, N. Peled, M. Reck, R. Hui, E.B. Garon, M. Boyer, T. Kurata, J. Yang, M.C. Pietanza, F. Souza & M.C. Garassino"]},"id":{"doi":["10.1016/j.annonc.2021.04.008"],"eki":["1763723674"]},"physDesc":[{"extent":"15 S."}],"recId":"1763723674","origin":[{"dateIssuedDisp":"22 April 2021","dateIssuedKey":"2021"}],"person":[{"family":"Rodríguez-Abreu","given":"Delvys","role":"aut","display":"Rodríguez-Abreu, Delvys"},{"display":"Bischoff, Helge","family":"Bischoff","role":"aut","given":"Helge"}],"relHost":[{"id":{"zdb":["2003498-2"],"issn":["1569-8041"],"eki":["320428796"]},"part":{"year":"2021","volume":"32","pages":"881-895","text":"32(2021), 7, Seite 881-895","extent":"15","issue":"7"},"corporate":[{"role":"isb","display":"European Society for Medical Oncology"}],"pubHistory":["1.1990 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"title":[{"subtitle":"official journal of the European Society for Medical Oncology","title":"Annals of oncology","title_sort":"Annals of oncology"}],"origin":[{"publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-","dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford"}],"disp":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC protocol-specified final analysis from KEYNOTE-189Annals of oncology","physDesc":[{"extent":"Online-Ressource"}],"recId":"320428796"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Available online 22 April 2021","Gesehen am 20.07.2021"],"title":[{"subtitle":"protocol-specified final analysis from KEYNOTE-189","title_sort":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC","title":"Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC"}]} | ||
| SRT | |a RODRIGUEZAPEMETREXED2220 | ||